You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GM2-ganglioside

Showing 1 - 25 of 7,740
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Immune Checkpoint Inhibitors Nephrotoxicity

Recruiting
  • Kidney Injury
  • Antineoplastics Toxicity
  • Early kidney damage biomarkers
  • Predisposition to kidney injury biomarkers
  • Salamanca, Spain
  • +1 more
Jul 26, 2022

To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast

Not yet recruiting
  • To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients
  • Monosialotetrahexose ganglioside sodium injection
  • (no location specified)
Mar 27, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Chemo-Induced Peripheral Neuropathy, Metastatic Breast Carcinoma Trial (Paclitaxel,

Not yet recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • (no location specified)
Feb 21, 2023

Breast Cancer Trial in Guangzhou (Ganglioside-monosialic acid, )

Completed
  • Breast Cancer
  • Ganglioside-monosialic acid
  • placebo
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Nov 3, 2021

Stroke, Ischemic Trial in Shenyang (Monosialoganglioside GM1)

Recruiting
  • Stroke, Ischemic
  • Monosialoganglioside GM1
  • Shenyang, Liaoning, China
    General Hospital of ShenYang Military Region
Aug 10, 2021

Chemo-Related Cognitive Impairment, Breast Cancer Trial in Guangzhou (Ganglioside-Monosialic Acid, 250ml normal saline (NS))

Recruiting
  • Chemotherapy-Related Cognitive Impairment
  • Breast Cancer
  • Ganglioside-Monosialic Acid
  • 250ml normal saline (NS)
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Mar 25, 2022

Infantile GM2 Gangliosidosis (Disorder) Trial in Kingston (TSHA-101)

Active, not recruiting
  • Infantile GM2 Gangliosidosis (Disorder)
  • TSHA-101
  • Kingston, Ontario, Canada
    Queen's University/Kingston Health Sciences Centre
Sep 12, 2022

GM1 and GM2 Gangliosidosis PROspective Neurological Disease

Recruiting
  • GM1 Gangliosidosis
  • +2 more
    • Oakland, California
    • +12 more
    Nov 16, 2022

    GM2 Gangliosidosis, Niemann-Pick Disease, Type C Trial in Curitiba, Porto Alegre, Rio De Janeiro (AZ-3102 (Dose 1), Placebo,

    Not yet recruiting
    • GM2 Gangliosidosis
    • Niemann-Pick Disease, Type C
    • AZ-3102 (Dose 1)
    • +2 more
    • Curitiba, Brazil
    • +2 more
    Feb 24, 2023

    Brain Metastases, Radiotherapy Side Effect, Cognitive Impairment Trial in Guangzhou (Monosialotetrahexosyl ganglioside (GM1),

    Recruiting
    • Brain Metastases
    • +4 more
    • Monosialotetrahexosyl ganglioside (GM1)
    • Control
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Nov 3, 2021

    Lysosomal Diseases, Gangliosidosis, GM1 Trial run by the NHGRI (biological, drug, diagnostic test, other, procedure, behavioral)

    Recruiting
    • Lysosomal Diseases
    • +2 more
    • AAV9-GLB1
    • +20 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 19, 2023

    A Natural History Study of the Gangliosidoses

    Recruiting
    • Tay-Sachs Disease
    • +4 more
      • Minneapolis, Minnesota
        University of Minnesota - Pediatric Genetics and Metabolism
      Feb 28, 2022

      Glycosphingolipid and Glycoprotein Lysosomal Storage Disorders

      Recruiting
      • Neurological Regression
      • +3 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Jan 14, 2023

        Psoriasis Vulgaris, Fractional CO2 Laser Trial in Assiut (Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone

        Completed
        • Psoriasis Vulgaris
        • Fractional CO2 Laser
        • Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone dipropionate 0.5 mg/gm
        • Fractional carbon dioxide (CO2) laser
        • Assiut, Egypt
          Assiut University
        Aug 23, 2023

        GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2 Trial in Worldwide (PBGM01)

        Recruiting
        • GM1 Gangliosidosis
        • +3 more
        • PBGM01
        • Oakland, California
        • +9 more
        Mar 10, 2022

        ICU Acquired Weakness Trial (patients who will receive 2 gm protein/kg/day will be evaluated by ultrasound for diaphragmatic

        Not yet recruiting
        • ICU Acquired Weakness
        • patients who will receive 2 gm protein/kg/day will be evaluated by ultrasound for diaphragmatic function and quadriceps muscle thickness
        • (no location specified)
        Sep 13, 2023

        GM2 Gangliosidosis, Supportive Care Trial in Kashan, Mashhad, Tehran (Miglustat)

        Recruiting
        • GM2 Gangliosidosis
        • Supportive Care
        • Kashan, Isfahan, Iran, Islamic Republic of
        • +2 more
        Oct 23, 2022

        DLBCL Trial in Suzhou (Chidamide, Azacitidine, obinutuzumab)

        Recruiting
        • Diffuse Large B-Cell Lymphoma
        • Suzhou, Jiangsu, China
          the First Affiliated Hospital of Soochow University
        Apr 10, 2023

        Neuroblastoma Trial in Cologne (antibody ch14.18, GM-CSF, IL-2 i.v.)

        Terminated
        • Neuroblastoma
        • antibody ch14.18
        • +4 more
        • Cologne, Germany
          University of Cologne
        Nov 3, 2022

        NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)

        Not yet recruiting
        • Carcinoma, Non-Small-Cell Lung
        • Carcinoma Breast
        • Suzhou, China
          Second Affiliated Hospital of Soochow University
        Oct 29, 2022

        Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)

        Active, not recruiting
        • Hepato-splenomegaly
        • +3 more
          • Cairo, Egypt
          • +4 more
          May 12, 2021

          HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor Trial in Seattle

          Active, not recruiting
          • HER2-positive Breast Cancer
          • +8 more
          • pNGVL3-hICD vaccine
          • +6 more
          • Seattle, Washington
            Fred Hutchinson Cancer Research Center/University of Washington
          Nov 1, 2022

          Recurrent Osteosarcoma Trial in Los Angeles, New York, Houston (humanized anti-GD2 antibody, GM-CSF)

          Recruiting
          • Recurrent Osteosarcoma
          • humanized anti-GD2 antibody
          • GM-CSF
          • Los Angeles, California
          • +2 more
          Dec 22, 2022

          Melanoma Trial in Beijing (OH2 injection, HX008 injection)

          Recruiting
          • Melanoma
          • OH2 injection
          • HX008 injection
          • Beijing, Beijing, China
            Peking University Cancer Hospital
          Jan 28, 2023

          Neuroblastoma Trial in New York (anti-GD2 murine IgG3 mAb 3F8)

          Completed
          Has Results
          • Neuroblastoma
          • anti-GD2 murine IgG3 monoclonal antibody 3F8
          • New York, New York
            Memorial Sloan-Kettering Cancer Center
          Apr 21, 2022